1,940 results on '"Kosten, Thomas R."'
Search Results
2. Disorders due to Substance Use: General Approaches
3. Cognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: a double-blind, randomized, sham-controlled study
4. Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample
5. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
6. Disorders Due to Substance Use: General Approaches
7. P50 inhibition defects, psychopathology and gray matter volume in patients with first-episode drug-naive schizophrenia
8. Letter to the Editor regarding ‘Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone’
9. Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene
10. Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial
11. Comorbid alcohol use and post-traumatic stress disorders: Pharmacotherapy with aldehyde dehydrogenase 2 inhibitors versus current agents
12. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans
13. Current status of vaccines for substance use disorders: A brief review of human studies
14. Highlights and insights from the 34th AAAP Annual Meeting and Scientific Symposium
15. Association of Symptoms of Attention Deficit and Hyperactivity with Problematic Internet Use among University Students in Wuhan, China During the COVID-19 Pandemic
16. Reflections on the FDA Draft Guidance for Development of Stimulant Use Disorder Treatments
17. Vaccines as Immunotherapies for Substance Use Disorders.
18. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review
19. A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naïve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms
20. A randomized trial of safety and pharmacodynamic interactions between a selective glucocorticoid receptor antagonist, PT150, and ethanol in healthy volunteers
21. Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge
22. The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia
23. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia
24. Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists
25. Lithium reduces impulsive decision making in transdiagnostic patients at high risk for suicide attempt recurrence: A randomized, double blind, placebo-controlled, crossover study
26. Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review
27. Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial
28. Psychosis and synthetic cannabinoids
29. Correlates of Risk for Disinhibited Behaviors in the Million Veteran Program Cohort.
30. DeepBiomarker2: Prediction of Alcohol and Substance Use Disorder Risk in Post-Traumatic Stress Disorder Patients Using Electronic Medical Records and Multiple Social Determinants of Health.
31. Comorbid alcohol use disorder and post‐traumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial with buprenorphine and naltrexone combination treatment
32. Dynamic functional thalamocortical dysconnectivity in schizophrenia correlates to antipsychotics response
33. Evidence-Based Pharmacotherapy for Cocaine, Amphetamine, and Methamphetamine Use Disorders
34. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels
35. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial
36. Altered anterior cingulate cortex to hippocampus effective connectivity in response to drug cues in men with cocaine use disorder
37. Reduction of depression-like behavior in rat model induced by ShRNA targeting norepinephrine transporter in locus coeruleus
38. miR-124-3p target genes identify globus pallidus role in suicide ideation recovery in borderline personality disorder
39. Adjuvants for Substance Abuse Vaccines
40. Vaccines for Methamphetamine Use Disorder
41. Vaccines for Treating Cocaine Use Disorders
42. Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder
43. The Opioid Epidemic Settlements: Who Will Benefit?
44. Contribution of IL-10 and its -592 A/C polymorphism to cognitive functions in first-episode drug-naive schizophrenia
45. 2022: The Year in Review
46. MicroRNA–mRNA networks are dysregulated in opioid use disorder postmortem brain: Further evidence for opioid-induced neurovascular alterations
47. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder
48. Serum IL-18 level, clinical symptoms and IL-18-607A/C polymorphism among chronic patients with schizophrenia in a Chinese Han population
49. Interaction of BDNF with cytokines in chronic schizophrenia
50. Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.